Henry Siu, MD
Interventional Cardiology · New York, NYNPI 1871777607
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $166,304 of the $233,967 with a category attached, or 71.1%. 42 manufacturers reported payments, led by Esperion Therapeutics, Inc. at 41.9% of the total. 2025 is the largest year on record at $69,348, more than ten times the $1,999 reported in 2019. Among interventional cardiology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,023 payments — averaging $228.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$98K
- Novo Nordisk$83K
- Bayer$20K
- Agepha Pharma FZ LLC$5K
- Abbott$4K
- Medtronic$3K
- plus $21K from 36 others
What the payments were for
- Consulting fees$24,02810%
- Speaking & faculty fees$166,30471%
- Travel & lodging$5,3682%
- Food & beverage$38,24716%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXLETOL$95,447
- NEXLIZET$94,876
- Ozempic$65,606
- Kerendia$9,956
- LODOCO$5,368
- HyperVue Imaging System$1,872
- Starlight Imaging Catheter$1,872
- Diamondback Peripheral$1,376
- Diamondback Coronary$1,185
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$544
- BioMonitor$468
- IGT D Coronary$421
- Repatha$400
- Licart$354
- GENERAL - STRUCTURAL HEART$344
- Coronary Orbital Atherectomy System$331
- Resolute$316
- ONYX FRONTIER$315
- OPTIS$307
- ClosureRFS$280
How this compares
$233,967 in reported general payments places this provider in the 95th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 708 | $685,202 |
| OzempicSemaglutide | 350 | $352,068 |
| KerendiaFinerenone | 292 | $328,586 |
| EntrestoSacubitril/Valsartan | 263 | $294,630 |
| FarxigaDapagliflozin Propanediol | 285 | $277,142 |
| EliquisApixaban | 163 | $183,782 |
| NexletolBempedoic Acid | 208 | $149,077 |
| MounjaroTirzepatide | 137 | $141,860 |
| VascepaIcosapent Ethyl | 244 | $132,281 |
| MultaqDronedarone Hcl | 83 | $111,129 |
| BrilintaTicagrelor | 129 | $94,830 |
| NexlizetBempedoic Acid/Ezetimibe | 136 | $93,039 |
| CamzyosMavacamten | 11 | $89,415 |
| JardianceEmpagliflozin | 104 | $88,270 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $50,195 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $1,510 | $685,202708 claims |
| Novo NordiskOzempic, Rybelsus | $82,747 | $373,682370 claims |
| AstraZenecaFarxiga, Brilinta | $1,143 | $371,972414 claims |
| BayerKerendia | $19,988 | $328,586292 claims |
| NovartisEntresto | $1,602 | $294,630263 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $97,988 | $242,116344 claims |
| PfizerEliquis | $29 | $183,782163 claims |
| Lilly USA, LLCMounjaro, Trulicity | $719 | $167,889165 claims |
| Sanofi-aventis U.S. LLCMultaq | $195 | $111,12983 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $1,127 | $89,41511 claims |
| Boehringer IngelheimJardiance | $945 | $88,270104 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $167 | $53,96982 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in New York
- Sahil ParikhNew York$1.6M
- Deepak BhattNew York$1.6M
- Martin LeonNew York$1.5M
- Sripal BangaloreNew York$482K
- Ajay KirtaneNew York$462K
- Prakash KrishnanNew York$387K
- Jaikirshan KhatriNew York$307K
- Samin SharmaNew York$291K
- Torsten VahlNew York$280K
- George DangasNew York$263K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.